Yep. I posted just before the conference call, which was indeed a good one.There was some interesting discussion around the ASCO conference and what it would mean going forward. 3,500 oncologists the majority of whom had not heard about Sirtex or Sirspheres. The study data has become a powerful foot in the door for the salesforce on the ground. Also the trend toward personalised courses of treatment and away from the historical standardised treatment will benefit SRX. The call is well worth listening to you can pretty much skip over the CFO's presentation, but Dr Cade's presentation is worth the time.
.
There was some interesting discussion around the ASCO conference and what it would mean going forward. 3,500 oncologists the majority of whom had not heard about Sirtex or Sirspheres. The study data has become a powerful foot in the door for the salesforce on the ground. Also the trend toward personalised courses of treatment and away from the historical standardised treatment will benefit SRX. The call is well worth listening to you can pretty much skip over the CFO's presentation, but Dr Cade's presentation is worth the time.
On the other forum there is at least one oncologist posting about SRX.
I haven't looked at the report in details... just glanced some of the headlines.
Back in May they said does sales growth to 10 months in FY15 was 22%. The data released today had growth = 19.8% for the year. It seems that growth slowed a bit in Q4... there's not enough information to work out the precise number, but back-of-envelope calculations suggest that Q4 growth was <10%. Not something of a huge worry... but the timing coincide with the ASCO conference.
It could very much be nothing, or a short term one-off reaction to the study headline by the doctors (in similar fashion to the share price dip). And otherwise it was a strong set of numbers demonstrating the operational leverage of the business.
Still seems to be plenty of selling interest when it gets to that 34 level.
I am pleased to report that the 2016 financial year has commenced strongly with global dose sales thus far tracking slightly ahead of our expectations. Indeed, in September the Company recorded for the first time ever in a single month over 1,000 dose sales globally. At this juncture our expectation is that dose sales in the 2016 financial year will grow at least in-line with historic trends, which over the last five years has shown a compound annual growth rate or CAGR of 19.7 per cent.
Dr Cade further commented “The additional recognition the SIRFLOX study will receive from publication in the Journal of Clinical Oncology is substantial, as this journal is consistently rated in the top 1% of all journals as measured by impact factor and is the leading oncology journal as measured by citations. It now provides our global sales force with a high impact, peer-reviewed publication to discuss with medical practitioners and other oncology professionals.”
The Journal of Clinical Oncology is the pre-eminent journal for medical professionals from all oncology disciplines and sub-specialities with more than 26,000 subscribers globally.
JCO has published the SIRFLOX study as a “Rapid Communication1”, which they define as a commitment to freely disseminate ground-breaking and practice-changing information so that it may benefit all readers and patients of the Journal.
Sirflox results getting published where and in a fashion that has real impact.
Thanks craft
Also, any idea when the next major annc is out?
Next Major trial results are the HCC trial result from The SARAH study due around April 2016 - then the Overall survival results for mCRC from the Firefox studies due early 2017.
But really the dosage sales are the key early indicators of how the oncology community is interpreting and pre-empting the outcomes via off label usage. On that front we have an update due tomorrow with earnings. Earnings could also be a catalyst if there is anything else at play. New R&D initiatives, acquisitions etc.
On the dose numbers for the first half - I would see anything below 5850 as an unexpected negative, above 6000 as an unexpected positive and anything in-between as neutral.
On the dose numbers for the first half - I would see anything below 5850 as an unexpected negative, above 6000 as an unexpected positive and anything in-between as neutral.
Numbers came in at 5728. +15.7% against guidance of 20% growth for the full year. Revenue growth was much higher than volume growth due to FX and $1000 price increase (to $16k a pot).... May be the price increase is having an impact?
The short term market probably won't love it that much today.
The first half result is consistent with our dose sales objectives for the full financial year which as previously indicated is anticipated to be least in-line with our five year compound annual growth rate or CAGR of 19.7 per cent.
I know SRX is on the nose at the moment, but a 5% fall because the Americas' President is leaving? People do move on to other things. He's leaving at the end of the FY, so it seems more routine than if he were leaving effective immediately.
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?